Merck and Ridgeback Biotherapeutics provided update on results from MOVe-OUT study of Molnupiravir in adults with COVID-19
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
On Nov. 26, 2021, the World Health Organization announced that the Technical Advisory Group on SARS-CoV-2 Virus Evolution…
On Nov. 23, 2021, the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized…
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of ‘Sangivamycin is highly effective against SARS-CoV-2 in vitro…
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
On Nov. 18, 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses…
On Nov. 16, 2021, Pfizer announced it had submitted an Emergency Use Authorization (EUA) of its investigational oral…
On Nov. 10, 2021, Meridian Bioscience announced that their Revogeneᆴ SARS-CoV-2 assay was granted Emergency Use Authorization by…
On Nov. 9, 2021, Moderna announced that it has submitted for a variation to the conditional marketing authorization…
On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…
On Nov. 5, 2021, the USDA’s (USDA) National Veterinary Services Laboratories announced confirmation of SARS-CoV-2 in two spotted…
On Nov. 5, 2021, scientists at the National Institutes of Health announced they had found that a process…
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…
On Nov. 3, 2021, the World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXINᆴ (developed…
On Nov. 2, 2021, the National Institutes of Health announced support for a four-year follow-up study on the…
On Nov. 1, 2021, the U.S. Food and Drug Administration (FDA) cleared the first 510(k) for a COVID-19…
On Oct. 27, 2021, Hologic announced that its Aptima SARS-CoV-2/Flu Assay was available for the simultaneous detection and…
On Oct. 27, 2021, RELIEF THERAPEUTICS announced that its wholly owned subsidiary, APR Applied Pharma Research, reported positive…
On Oct. 21, 2021, the National Institutes of Health announced that a booster dose of the mRNA-1273 COVID-19…
On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…
On Oct. 19, 2021, National Science Foundation funded scientists at the Yale School of Public Health and the…
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…
On Oct. 14, 2021, the U.S. Department of Agriculture’s Agriculture Research Service (ARS) announced confirmation of SARS-CoV-2 (the…
On Oct. 14, 2021, The NIH Rapid Acceleration of Diagnostics (RADx) initiative announced that it has issued contract…
On Oct. 14, 2021, Cepheid announced it had received the CE mark for Xpert Xpress CoV-2/Flu/RSV plus, a…
On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use…
On Oct. 7, 2021, Vaxart announced that a Duke University-led study published in bioRxiv showed that Vaxart’s (investigational…
On Oct. 6, 2021, the U.S. Department of Agriculture’s Agriculture Research Service (ARS) announced confirmation of SARS-CoV-2 (the…
On Oct. 5, 2021, PerkinElmer announced that the U.S. Food and Drug Administration had provided Emergency Use Authorization…